Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 11Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Leukemia 2Hematologic Neoplasms 2Leukemia, Myeloid 1Disease 1

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × CPX-351 × Clear all
NCT00788892 2018-01-12

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

Jazz Pharmaceuticals

Phase 2 Completed
126 enrolled 12 charts
Other hematologic neoplasm

Disease, Leukemia, Leukemia, Myeloid, Acute

NCT00822094 2017-11-24

Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)

Jazz Pharmaceuticals

Phase 2 Completed
126 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡